Chemomab Therapeutics (NASDAQ:CMMB) Releases Earnings Results, Misses Expectations By $0.23 EPS

Chemomab Therapeutics (NASDAQ:CMMB) issued its quarterly earnings data on Wednesday. The company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.23), Zacks reports.

Chemomab Therapeutics Price Performance

NASDAQ:CMMB traded up $0.01 during trading hours on Wednesday, hitting $1.93. The stock had a trading volume of 2,240 shares, compared to its average volume of 89,674. The company has a 50 day simple moving average of $1.71 and a two-hundred day simple moving average of $1.71. The firm has a market capitalization of $13.86 million, a price-to-earnings ratio of -0.87 and a beta of 0.65. Chemomab Therapeutics has a one year low of $1.35 and a one year high of $4.12.

Institutional Trading of Chemomab Therapeutics

An institutional investor recently bought a new position in Chemomab Therapeutics stock. XTX Topco Ltd bought a new position in Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 19,013 shares of the company’s stock, valued at approximately $31,000. XTX Topco Ltd owned about 0.31% of Chemomab Therapeutics as of its most recent filing with the SEC. 46.05% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Chemomab Therapeutics in a report on Wednesday, August 5th. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus target price of $25.00.

About Chemomab Therapeutics

Chemomab Therapeutics (NASDAQ:CMMB) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next-generation antibody therapies. The company leverages a proprietary antibody engineering platform to generate novel bi- and multi-specific antibodies with applications in oncology, infectious diseases and inflammatory disorders. By combining cutting-edge discovery tools with translational research, Chemomab aims to advance promising candidates from early proof-of-concept through clinical development.

Among its pipeline programs, Chemomab is advancing antibody candidates designed to target key tumor antigens and pathogen-specific epitopes.